Trial Details
ACTIVE_NOT_RECRUITINGBasic Information
| Clinical ID | c2419 |
|---|---|
| Identifier | NCT03519945 |
| Trial Title | A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: Mirikizumab |
Participant Information
| Sponsor | Eli Lilly and Company |
|---|---|
| City | Dothan |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2018-07-18 |
|---|---|
| Primary Completion Date | 2026-07 |
| Completion Date | 2027-12 |